Belzutifan listed on PBS 1st December 2024

MedNews announce “MSD leads PBS Christmas gift list”

Advocating alongside VHL patients is the very heart of what NECA do, we are absolutely thrilled with yesterday’s inclusion of  Belzutifan on the PBS listing effective 1 December 2024. Thank  you to each and every patient and healthcare professional that advocated, signed petitions, lobbied, met with local MPs and attended the NECA VHL Parliamentary event, this positive outcome is the work of a united voice so that VHL patients receive the equitable treatment options they deserve.

Meredith Cummins, CEO of NeuroEndocrine Cancer Australia stated “words cannot express how fabulous this is for the VHL community – there is now HOPE for so many generations and this is no longer just a dream we wanted to come true!”

Welireg (Belzutifan) listed on PBS 1st December, a great Christmas gift for VHL patients.

Read full article here.

mednews front page

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

INCA Annual Summit 2026

2026 ACNNP and CPSP Collaboration Forum

NECA welcomes PBS listing of Selpercatinib for medullary thyroid cancer

Vote now: NeuroEndocrine Cancer Australia is entered in SIX Patients Australia Awards!

Neuroendocrine Cancer Day

Neuroendocrine Cancer Day is on 10 November, and every bit of support counts.

Create an event, share your artwork, or donate on our ‘Double Your Impact’ days. There are so many ways to stand with the NET community.